Infanrix-Ipv (Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A)

The vaccine contains inactivated poliovirus type 3 antigens and pertussis filamentous haemagglutinin. When injected intramuscularly, these antigens are processed by antigen‑presenting cells, triggering B‑cell and T‑cell responses that generate specific antibodies and cellular immunity, thereby protecting the recipient from future infection.

The dosing schedule for Infanrix-Ipv is determined by the prescribing healthcare professional based on the patient’s age, immunization history, and local guidelines. The prescriber will specify the volume and timing of each injection to ensure optimal protection.

The safety of Infanrix-Ipv in pregnancy has not been definitively established, and it is generally recommended to vaccinate before pregnancy when possible. Breastfeeding is not a contraindication, but mothers should discuss any concerns with their healthcare provider.

To place an order, submit an enquiry on the Infanrix-Ipv product page at gnhindia.com, providing the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then replies with pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Infanrix-Ipv combines inactivated poliovirus type 3 and pertussis haemagglutinin in a single injectable formulation, reducing the number of injections needed compared with separate vaccines. It meets EU regulatory standards and offers comparable immunogenicity to other licensed combination vaccines while simplifying the immunization schedule.

Infanrix-Ipv must be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. It should not be frozen or shaken. During transport, a validated cold‑chain system is required to maintain temperature stability until administration.

Infanrix-Ipv is given as an intramuscular injection, typically into the anterolateral thigh in infants or the deltoid muscle in older children. The injection is performed by a qualified healthcare professional following aseptic technique and the prescribed dosing schedule.

Serious adverse events, although rare, include anaphylaxis, seizures, high fever, encephalopathy, and Guillain‑Barré syndrome. Immediate medical attention is required if any signs of severe allergic reaction or neurological symptoms occur after vaccination.

Infanrix-Ipv should not be administered to individuals with a known severe allergy to any component of the vaccine, including the inactivated poliovirus or pertussis haemagglutinin. It is also contraindicated in persons who have experienced a previous severe reaction to a similar vaccine.